Trial Profile
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Thalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Jun 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 01 Jun 2012 Results published in the European Journal of Haematology.
- 08 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.